Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandeep Dutta

Showing results (71-80 of 114) with videos related to

Pageof 12
Sort By:
Clinical Pharmacology in Drug Development|June 19, 2021
Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy SubjectsAshit Trivedi, Fady I Malik, Pegah Jafarinasabian, et al.
Clinical Pharmacokinetics|March 26, 2021
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv MecarbilAshit Trivedi, Rajneet K Oberoi, Pegah Jafarinasabian, et al.
Pediatric Neurology|May 29, 2004
Divalproex-ER pharmacokinetics in older children and adolescentsSandeep Dutta, Yiming Zhang, Jeannine M Conway, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2015
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without DasabuvirJennifer R King, Sandeep Dutta, Daniel Cohen, et al.
Clinical Drug Investigation|June 10, 2021
Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult SubjectsAshit Trivedi, Mia Mackowski, Pegah Jafarinasabian, et al.
Clinical Pharmacology in Drug Development|July 17, 2021
Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy SubjectsAshit Trivedi, Winnie Sohn, Pegah Jafarinasabian, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 19, 2023
Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migrainePo-Wei Chen, Mats O Karlsson, Sebastian Ueckert, et al.
Journal of Pharmaceutical Sciences|November 20, 2016
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human StudyChih-Wei Lin, Sandeep Dutta, Armen Asatryan, et al.
Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention|May 12, 2006
Quantification of emphysema severity by histogram analysis of CT scansPaulo R S Mendonça, Dirk R Padfield, James C Ross, et al.
Clinical Drug Investigation|April 6, 2017
Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III StudiesChih-Wei Lin, Rajeev Menon, Wei Liu, et al.
Pageof 12

Showing results (71-80 of 114) with videos related to

Sort By:
Pageof 12
Clinical Pharmacology in Drug Development|June 19, 2021
Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy SubjectsAshit Trivedi, Fady I Malik, Pegah Jafarinasabian, et al.
Clinical Pharmacokinetics|March 26, 2021
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv MecarbilAshit Trivedi, Rajneet K Oberoi, Pegah Jafarinasabian, et al.
Pediatric Neurology|May 29, 2004
Divalproex-ER pharmacokinetics in older children and adolescentsSandeep Dutta, Yiming Zhang, Jeannine M Conway, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2015
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without DasabuvirJennifer R King, Sandeep Dutta, Daniel Cohen, et al.
Clinical Drug Investigation|June 10, 2021
Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult SubjectsAshit Trivedi, Mia Mackowski, Pegah Jafarinasabian, et al.
Clinical Pharmacology in Drug Development|July 17, 2021
Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy SubjectsAshit Trivedi, Winnie Sohn, Pegah Jafarinasabian, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 19, 2023
Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migrainePo-Wei Chen, Mats O Karlsson, Sebastian Ueckert, et al.
Journal of Pharmaceutical Sciences|November 20, 2016
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human StudyChih-Wei Lin, Sandeep Dutta, Armen Asatryan, et al.
Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention|May 12, 2006
Quantification of emphysema severity by histogram analysis of CT scansPaulo R S Mendonça, Dirk R Padfield, James C Ross, et al.
Clinical Drug Investigation|April 6, 2017
Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III StudiesChih-Wei Lin, Rajeev Menon, Wei Liu, et al.
Pageof 12